Regulatory25 Jun 2026, 10:03 am
Concord Biotech Unit-II Passes Kenya and Uganda Regulatory Inspections
AI Summary
Concord Biotech Ltd announced the successful completion of inspections by the Pharmacy and Poisons Board (PPB) of Kenya and the National Drug Authority (NDA) of Uganda at its Unit-II formulation facility. The inspections, conducted from June 18 to June 24, 2026, concluded successfully. This milestone is expected to strengthen Concord Biotech's global manufacturing and regulatory footprint, reinforcing its commitment to high quality and regulatory standards as part of its international growth strategy.
Key Highlights
- Unit-II formulation facility passed inspections by Kenyan and Ugandan regulatory bodies.
- Successful inspections reinforce global manufacturing and regulatory compliance.
- Marks a significant milestone in the company's global growth journey.
- Demonstrates commitment to high standards of quality and regulatory excellence.
Price Impact
More from CONCORDBIO